

Kiichiro Fujisaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7370216/publications.pdf>

Version: 2024-02-01

29
papers

477
citations

623734

14
h-index

713466

21
g-index

29
all docs

29
docs citations

29
times ranked

683
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 529-538.	0.7	60
2	Association Between Serum Phosphate Levels and Stroke Risk in Patients Undergoing Hemodialysis. <i>Stroke</i> , 2016, 47, 2189-2196.	2.0	54
3	Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 84-92.	1.9	47
4	Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. <i>Clinical and Experimental Nephrology</i> , 2003, 7, 279-283.	1.6	31
5	Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. <i>Clinical and Experimental Nephrology</i> , 2008, 12, 398-402.	1.6	29
6	Clinical Significance of Fronto-Temporal Gray Matter Atrophy in Executive Dysfunction in Patients with Chronic Kidney Disease: The VCOHP Study. <i>PLoS ONE</i> , 2015, 10, e0143706.	2.5	27
7	Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in hemodialysis patients: the Q-Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1152-1160.	0.7	24
8	Improvement in spatial memory dysfunction by telmisartan through reduction of brain angiotensin II and oxidative stress in experimental uremic mice. <i>Life Sciences</i> , 2014, 113, 55-59.	4.3	23
9	Pre-dialysis Hyponatremia and Change in Serum Sodium Concentration During a Dialysis Session Are Significant Predictors of Mortality in Patients Undergoing Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 342-350.	0.8	23
10	The Fukuoka Kidney disease Registry (FKR) Study: design and methods. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 465-473.	1.6	21
11	Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: the Q-cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 856-864.	0.7	19
12	The Incidence and Associated Factors of Sudden Death in Patients on Hemodialysis: 10-Year Outcome of the Q-Cohort Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 306-318.	2.0	18
13	Midodrine Hydrochloride and l-threo-3,4-dihydroxy-Phenylserine Preserve Cerebral Blood Flow in Hemodialysis Patients With Orthostatic Hypotension. <i>Therapeutic Apheresis and Dialysis</i> , 2007, 11, 49-55.	0.9	17
14	A J-shaped association between serum uric acid levels and poor renal survival in female patients with IgA nephropathy. <i>Hypertension Research</i> , 2017, 40, 291-297.	2.7	16
15	Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. <i>Hypertension Research</i> , 2014, 37, 993-998.	2.7	14
16	Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. <i>Renal Failure</i> , 2016, 38, 390-396.	2.1	12
17	Extended Swanâ€œNeck Catheter With Upper Abdominal Exitâ€œSite Reduces Peritoneal Dialysisâ€œRelated Infections. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 158-164.	0.9	8
18	Prognostic value of pre-dialysis blood pressure and risk threshold on clinical outcomes in hemodialysis patients. <i>Medicine (United States)</i> , 2018, 97, e13485.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Hypocomplementemic urticarial vasculitis syndrome with gastrointestinal vasculitis and crescentic membranoproliferative glomerulonephritis without immune complex deposits. CEN Case Reports, 2020, 9, 30-35.	0.9	6
20	Membranoproliferative glomerulonephritis with predominant IgG2 and IgG3 deposition in a patient with IgG4-related disease. BMC Nephrology, 2015, 16, 173.	1.8	5
21	Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. Kidney and Blood Pressure Research, 2021, 46, 173-184.	2.0	4
22	The Association between Dialysis Dose and Risk of Cancer Death in Patients Undergoing Hemodialysis: The Q-Cohort Study. Internal Medicine, 2020, 59, 1141-1148.	0.7	3
23	Repeated Paradoxical Brain Infarctions in a Patient on Self-Managed Home Hemodialysis Using a Long-Term Indwelling Catheter. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, e183-e185.	1.6	2
24	Asymptomatic Brain Edema after Hemodialysis Initiation in a Patient with Severe Uremia. Case Reports in Medicine, 2017, 2017, 1-6.	0.7	2
25	Immobilization-induced severe hypercalcaemia successfully treated with reduced dose of zoledronate in a maintenance haemodialysis patient. Nephrology, 2018, 23, 963-964.	1.6	2
26	Anti-glomerular basement membrane disease complicated with posterior reversible encephalopathy syndrome and subcortical cerebral hemorrhage: a case report and review of the literature. CEN Case Reports, 2020, 9, 278-284.	0.9	2
27	Rapidly Progressive Glomerulonephritis with Delayed Appearance of Anti-Glomerular Basement Membrane Antibody Successfully Treated with Multiple Courses of Steroid Pulse Therapy. Case Reports in Nephrology and Dialysis, 2019, 9, 25-32.	0.6	0
28	High low-density lipoprotein cholesterol as an independent risk factor for coronary restenosis in hemodialysis patients undergoing percutaneous coronary interventions. Therapeutic Apheresis and Dialysis, 2021, 25, 296-303.	0.9	0
29	A non-immunocompromised host with nontuberculous mycobacteria-associated tubulointerstitial nephritis. CEN Case Reports, 2022, , 1.	0.9	0